Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Revolution has set itself a mission to revolutionize treatment for patients with RAS addicted cancers. See why I upgrade RVMD ...

Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

today announced key clinical updates from its RAS(ON) inhibitor portfolio. The data to be presented during an investor webcast today at 8:00 a.m. Eastern Time (ET) will focus on updated clinical ...

Revolution Medicines (RVMD) announced key clinical updates from its RAS(ON) inhibitor portfolio. The data to be presented during an investor webcast today at 8:00 a.m. Eastern Time will focus on ...

RAS(ON) Inhibitor Combination Studies: RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy ...